Unichem Labs gets USFDA nod for Amitriptyline HCl Tablets

Published On 2021-05-21 06:56 GMT   |   Update On 2021-05-21 06:56 GMT

Mumbai: Drugmajor, Unichem Laboratories Limited, has recently announced that the company has received ANDA approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the United States Food and Drug Administration (USFDA).The product is a generic version of ELAVIL (Amitriptyline Hydrochloride) 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg of...

Login or Register to read the full article

Mumbai: Drugmajor, Unichem Laboratories Limited, has recently announced that the company has received ANDA approval for its Amitriptyline HCl Tablets USP, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg from the United States Food and Drug Administration (USFDA).

The product is a generic version of ELAVIL (Amitriptyline Hydrochloride) 10 mg, 25 mg, 50 mg, 75 mg, 100 mg and 150 mg of AstraZeneca Pharmaceuticals LP.

Amitriptyline HCl Tablets are indicated for the relief of symptoms of depression.

The product will be commercialized from Unichem's Goa Plant.

Read also: Unichem Labs gets USFDA nod for hypertension drug Guanfacine

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.




Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News